poisar

Stock

Medicus Pharma Ltd. MDCX

$0.40+1.26%

Overview

MDCX market data

Price History

MDCX price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.05
Diluted earnings per share over the trailing twelve months.
Beta
1.56
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.25 – $3.12
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $22.4 · P/B 9.51.

Company news

9 captured
Medicus Pharma shares are trading higher after the company announced that it has received written feedback from the FDA and central Institutional Review Board approval, with modifications, for its optimized Phase 2 clinical study of Teverelix in men following a first episode of acute urinary retention.Benzinga · Jul 16, 2026, 2:56 PM
Medicus Pharma Announces Positive FDA Feedback For Its Optimized Phase 2 Clinical Trial Of Teverelix In Men Following A First Episode Of Acute Urinary RetentionBenzinga · Jul 16, 2026, 11:33 AM
Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026Benzinga · Jun 22, 2026, 12:05 PM
Medicus Pharma To Present Showcase SkinJect Registrational Strategy, Teverelix Precision Medicine Program At 2026 Bio International ConferenceBenzinga · Jun 22, 2026, 11:40 AM
Medicus Pharma Files Rare Pediatric Disease Designation Request To FDA For SkinJect Microneedle Array Patch To Treat Basal Cell Carcinoma In Participants With Gorlin SyndromeBenzinga · Jun 15, 2026, 11:40 AM
Medicus Pharma Submits IND Application To DOH For PRECISION-E2, Phase 2a Genomics-Enabled Clinical Trial Evaluating Teverelix In Women With Symptomatic Endometriosis In UAEBenzinga · Jun 11, 2026, 11:34 AM
Medicus Pharma Submits Modification Application Through European Union Clinical Trials Information System For Its Phase 2b Trial Of Teverelix In Advanced Prostate CancerBenzinga · Jun 8, 2026, 11:45 AM
Medicus Pharma Receives $22M In Non-Dilutive FinancingBenzinga · May 28, 2026, 12:25 PM
Medicus Pharma Q1 EPS $(0.31) Misses $(0.19) EstimateBenzinga · May 14, 2026, 8:34 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock